Swiss National Bank’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Swiss National Bank’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-5,860	Closed	-$197K	–	2577
2019 Q1	$197K	Hold	5,860	–	–	﹤0.01%	2495
2018 Q4	$171K	Hold	5,860	–	–	﹤0.01%	2524
2018 Q3	$361K	Hold	5,860	–	–	﹤0.01%	2464
2018 Q2	$432K	Buy	5,860 +1,430	+32%	+$111K	﹤0.01%	2472
2018 Q1	$291K	Hold	4,430	–	–	﹤0.01%	2460
2017 Q4	$373K	Hold	4,430	–	–	﹤0.01%	2466
2017 Q3	$512K	Hold	4,430	–	–	﹤0.01%	2375
2017 Q2	$517K	Hold	4,430	–	–	﹤0.01%	2397
2017 Q1	$547K	Buy	4,430 +1,500	+51%	+$196K	﹤0.01%	2350
2016 Q4	$399K	Hold	2,930	–	–	﹤0.01%	2466
2016 Q3	$583K	Hold	2,930	–	–	﹤0.01%	2276
2016 Q2	$380K	Sell	2,930 -600	-17%	-$66.8K	﹤0.01%	2467
2016 Q1	$319K	Buy	3,530 +640	+22%	+$69.7K	﹤0.01%	2472
2015 Q4	$586K	Hold	2,890	–	–	﹤0.01%	2170
2015 Q3	$420K	Buy	2,890 +2,190	+313%	+$402K	﹤0.01%	2270
2015 Q2	$149K	Buy	+700	New	+$172K	﹤0.01%	2565

Other funds holding BLCM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Swiss National Bank's BLCM Position: Q2 2019 in Review

Swiss National Bank sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2019, closing a stake of 5,860 shares — an estimated $197K sold.

Swiss National Bank first reported a position in BLCM in Q2 2015 and held it in 16 quarters. The position peaked at $586K in Q4 2015. 79 funds tracked by Wall St. Rank hold BLCM as of Q2 2019.

Swiss National Bank reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
Swiss National Bank sold 5,860 Bellicum Pharmaceuticals, Inc. shares in Q2 2019, an estimated $197K.
Swiss National Bank first reported a position in Bellicum Pharmaceuticals, Inc. in Q2 2015 and held it in 16 quarters.
Swiss National Bank's Bellicum Pharmaceuticals, Inc. position peaked at $586K in Q4 2015.
79 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2019.

Based on Swiss National Bank's 13F filing for Q2 2019, filed 2 Aug 2019.